New strategies for the management of no-reflow after primary percutaneous coronary intervention

References

• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet361, 13–20 (2003).
   PubMed Web of Science ®Google Scholar
• Kloner RA, Ganote CE, Jennings RB. The ‘no reflow’ phenomenon after temporary occlusion in the dog. J. Clin. Invest.54, 1496–1508 (1974).
   PubMed Web of Science ®Google Scholar
• Summers WK, Jamison RL. The no reflow phenomenon in renal ischemia. Lab. Invest.25, 635–643 (1971).
   PubMed Web of Science ®Google Scholar
• Majno GA, Chaing J, Wright RL. No reflow after cerebral ischemia. Lancet2, 569–570 (1967).
   Web of Science ®Google Scholar
• Willms-Kretschmer K., Majno G. Ischemia of the skin. Electron microscopic study of vascular injury. Am. J. Pathol.54, 327–343 (1969).
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter. Cardiovasc. Interv.72, 950–957 (2008)
   PubMed Web of Science ®Google Scholar
• Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur. Heart J.22, 729–739 (2001).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E; TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation105, 1909–1913 (2002).
   PubMed Web of Science ®Google Scholar
• McLaughlin MG, Stone GW, Aymong E et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J. Am. Coll. Cardiol.44, 1215–1223 (2004).
   PubMed Web of Science ®Google Scholar
• Bolognese L, Carrabba N, Parodi G et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation109, 1121–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Galiuto L, Garramone B, Scarà A et al.; AMICI Investigators. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J. Am. Coll. Cardiol.51, 552–559 (2008).
   PubMed Web of Science ®Google Scholar
• Soraja P, Gersh BJ, Costantini C et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur. Heart J.26, 667–674 (2005).
   PubMedGoogle Scholar
• Brosh D, Assali AR, Mager A et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am. J. Cardiol.99, 442–445 (2007).
   PubMed Web of Science ®Google Scholar
• Henriques JP, Zijlstra F, van’t Hof AW et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation107, 2115–2119 (2003).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Tiroch K, Fusaro M et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol.55, 2383–2389 (2010).
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J. Am. Coll. Cardiol.54, 281–292 (2009).
   PubMed Web of Science ®Google Scholar
• Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again prevention is better than treatment. Eur. Heart J.31, 2449–2445 (2010).
   PubMed Web of Science ®Google Scholar
• Tranum-Jensen J, Janse MJ, Fiolet WT, Krieger WJ, D’Alnoncourt CN, Durrer D. Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine. Circ. Res.49, 364–381 (1981).
   PubMed Web of Science ®Google Scholar
• Turschner O, D’hooge J, Dommke C et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur. Heart J.25, 794–803 (2004).
   PubMed Web of Science ®Google Scholar
• Iwakura K, Ito H, Kawano S et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J. Am. Coll. Cardiol.38, 472–477 (2001).
   PubMed Web of Science ®Google Scholar
• Heusch G, Kleinbongard P, Böse D et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation120, 1822–1836 (2009).
   PubMed Web of Science ®Google Scholar
• Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res. Cardiol.101, 373–382 (2006).
   PubMed Web of Science ®Google Scholar
• Hori M, Inoue M, Kitakaze M et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am. J. Physiol.250, H509–H518 (1986).
   Google Scholar
• Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am. J. Physiol. Heart Circ. Physiol.282, H611–H614 (2002).
   Google Scholar
• Ross J Jr. Myocardial perfusion–contraction matching. Circulation83, 1076–1083 (1991).
   PubMed Web of Science ®Google Scholar
• Dorge H, Neumann T, Behrends M et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am. J. Physiol. Heart Circ. Physiol.279, H2587–H2592 (2000).
   PubMedGoogle Scholar
• Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest122, 1322–1332 (2002).
   PubMed Web of Science ®Google Scholar
• Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch. Pathol.70, 68–78 (1960).
   PubMedGoogle Scholar
• Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler. Thromb. Vasc. Biol.2258–2265 (2007).
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and Type 2 diabetes. Diabetes Vasc. Dis. Res.2, 136–143 (2005).
   PubMedGoogle Scholar
• Iwakura K, Ito H, Ikushima M et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J. Am. Coll. Cardiol.41, 1–7 (2003).
   PubMed Web of Science ®Google Scholar
• Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation75, 292–298 (1987).
   PubMed Web of Science ®Google Scholar
• Galiuto L, Lombardo A, Maseri A et al. Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart89, 731–737 (2003).
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation105, 656–662 (2002).
   PubMed Web of Science ®Google Scholar
• Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N. Engl. J. Med.357, 1631–1638 (2007).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Ongen Z, Guindy R et al.; RIVIERA Investigators. Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. Int. J. Cardiol.129(3), 379–387 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao JL, Yang YJ, You SJ et al. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron. Artery Dis.17, 463–469 (2006).
   PubMed Web of Science ®Google Scholar
• Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K. The myocardial Na+–H+ exchange: structure, regulation, and its role in heart disease. Circ. Res.85, 777–786 (1999).
   PubMed Web of Science ®Google Scholar
• Théroux P, Chaitman BR, Danchin N et al. Inhibition of the sodium–hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation102, 3032–3038 (2000).
   PubMed Web of Science ®Google Scholar
• Zeymer U, Suryapranata H, Monassier JP et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J. Am. Coll. Cardiol.38, 1644–1650 (2001).
   PubMed Web of Science ®Google Scholar
• Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev.83, 1113–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am. J. Physiol. Heart Circ. Physiol.296, H1705–H1720 (2009).
   PubMed Web of Science ®Google Scholar
• Jerome SN, Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am. J. Physiol.268, H2063–H2067 (1995).
   Google Scholar
• Malmberg K, Rydén L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol.26, 56–65 (1995).
   Web of Science ®Google Scholar
• Malmberg K, Rydén L, Wedel H et al.; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J.26, 650–661 (2005).
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A et al.; DIGAMI 2 Investigators. The impact of glucose-lowering treatment on long-term prognosis in patients with Type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur. Heart J.29, 166–176 (2008).
   PubMed Web of Science ®Google Scholar
• Lefer DJ. Statins as potent anti-inflammatory drugs. Circulation106, 2041–2042 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao J-L, Yang Y-J, Cui C-J, You S-J, Gao R-L. Pretreatment with simvastatin reduced myocardial no-reflow by opening mitochondrial KATP channel. Br. J. Pharmacol.149, 243–249 (2006).
   PubMed Web of Science ®Google Scholar
• Iwakura K, Ito H, Kawano S et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J.27, 534–539 (2006).
   PubMed Web of Science ®Google Scholar
• Ambrosio G, Del Pinto M, Tritto I et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patient in the Global Registry of Acute Coronary Events. Eur. Heart J.31, 430–438 (2010).
   PubMed Web of Science ®Google Scholar
• Kloner RA, Shook T, Przyklenk K et al.; for the TIMI 4 Investigators. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation91, 37–47 (1995).
   PubMed Web of Science ®Google Scholar
• Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N. Engl. J. Med.334, 7–12 (1996).
   PubMed Web of Science ®Google Scholar
• Karila-Cohen D, Czitrom D, Brochet E et al. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur. Heart J.20, 1724–1730 (1999).
   PubMed Web of Science ®Google Scholar
• Przyklenk K, Bauer B, Ovize M et al. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation87, 893–899 (1993).
   PubMed Web of Science ®Google Scholar
• Pell TJ, Baxter GF, Yellon DM et al. Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. Am. J. Physiol.275, H1542–H1547 (1998).
   Google Scholar
• Gho BC, Schoemaker RG, Van Den Doel MA et al. Myocardial protection by brief ischemia in non-cardiac tissue. Circulation94, 2193–2200 (1996).
   PubMed Web of Science ®Google Scholar
• Bøtker HE, Kharbanda R, Schmidt MR et al. Remote ischemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet375, 727–734 (2010).
   Google Scholar
• Burzotta F, Trani C, Romagnoli E et al. Manual thrombus-aspiration improves myocardial reperfusion: the Randomized Evaluation of The Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in Primary and Rescue Angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol.46, 371–376 (2005).
   PubMed Web of Science ®Google Scholar
• Galiuto L, Garramone B, Burzotta F et al. REMEDIA Investigators. Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA trial. J. Am. Coll. Cardiol.48, 1355–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Burzotta F, Testa L, Giannico F et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int. J. Cardiol.123, 313–321 (2008).
   PubMed Web of Science ®Google Scholar
• Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur. Heart J.29(24), 2989–3001 (2008).
   PubMed Web of Science ®Google Scholar
• Svilaas T, Vlaar PJ, van der Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med.358, 557–567 (2008).
   PubMed Web of Science ®Google Scholar
• De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive Manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur. Heart J.29, 3002–3010 (2008).
   PubMed Web of Science ®Google Scholar
• Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J. Am. Coll. Cardiol.44, 1103–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis204, 334–341 (2009).
   PubMed Web of Science ®Google Scholar
• Hansen PR, Thibault H, Abdulla J. Postconditioning during primary percutaneous coronary intervention: a review and meta-analysis. Int. J. Cardiol.144, 22–25 (2010).
   PubMed Web of Science ®Google Scholar
• Lønborg J, Kelbaek H, Vejlstrup N et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ. Cardiovasc. Interv.3, 34–41 (2010).
   PubMed Web of Science ®Google Scholar
• Sörensson P, Saleh N, Bouvier F et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart96, 1710–1715 (2010).
   Google Scholar
• Lønborg J, Holmvang L, Kelbæk H et al. ST-segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am. Heart J.160, 1085–1091 (2010).
   PubMed Web of Science ®Google Scholar
• Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: experimental and clinical observations. Am. Heart J.149, 580–584 (2005).
   PubMed Web of Science ®Google Scholar
• Cameron AJV, Hutton L, Kenmure ACF, Murdoch WR. Haemodynamic and metabolic effects of hyperbaric oxygen in myocardial infarction. Lancet2, 833–887 (1966).
   PubMed Web of Science ®Google Scholar
• Sterling DL, Thornton JD, Swafford A et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation88, 1931–1936 (1993).
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Bartorelli AL, Fabbiocchi F et al. Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior ST-elevation myocardial infarction. Catheter. Cardiovasc. Interv.67, 859–865 (2006).
   PubMed Web of Science ®Google Scholar
• O’Neill WW, Martin JL, Dixon SR et al. Acute myocardial infarction with hyperoxemic therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J. Am. Coll. Cardiol.50(5), 397–405 (2007).
   PubMed Web of Science ®Google Scholar
• Petronio AS, De Carlo M, Ciabatti N et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am. Heart J.150, 1015 (2005).
   PubMed Web of Science ®Google Scholar
• Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction trial. Circulation118, 49–57 (2008).
   PubMed Web of Science ®Google Scholar
• Gu YL, Kampinga MA, Wieringa WG et al. Intracoronary versus intravenous administration of abciximab in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial. Circulation122(25), 2709–2717 (2010).
   PubMed Web of Science ®Google Scholar
• Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am. J. Cardiol.94, 35–39 (2004).
   PubMed Web of Science ®Google Scholar
• Claeys MJ, Bosmans J, De Ceuninck M et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am. J. Cardiol.94, 9–13 (2004).
   PubMed Web of Science ®Google Scholar
• Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation101, 2154–2159 (2010).
   Google Scholar
• Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter. Cardiovasc. Interv.71, 283–289 (2008).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Puma JA, Barbagelata NA et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J. Am. Coll. Cardiol.34, 1711–1720 (1999).
   PubMed Web of Science ®Google Scholar
• Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol.45, 1775–1780 (2005).
   PubMed Web of Science ®Google Scholar
• Micari A, Belcick TA, Balcells EA et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am. J. Cardiol.96, 1410–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Amit G, Cafri C, Yaroslavtsev S, Fuchs S et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am. Heart J.152, 887.e9–e14 (2006).
   PubMedGoogle Scholar
• Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int. Heart J.48, 423–433 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii H, Ichimiya S, Kanashiro M et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation112, 1284–1288 (2005).
   PubMed Web of Science ®Google Scholar
• Ito H, Taniyama Y, Iwakura K et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol.33, 654–660 (1999).
   PubMed Web of Science ®Google Scholar
• Ono H, Osanai T, Ishizaka H et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am. Heart J.148, E15 (2004).
   PubMed Web of Science ®Google Scholar
• Hayashi M, Tsutamoto T, Wada A et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J. Am. Coll. Cardiol.37, 1820–1826 (2001).
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Ito H, Iwakura K et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J. Am. Coll. Cardiol.30, 1193–1199 (1997).
   PubMed Web of Science ®Google Scholar
• Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter. Cardiovasc. Interv.57, 444–451 (2002).
   PubMed Web of Science ®Google Scholar
• Piot C, Croisille P, Staat P et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med.359, 473–481 (2008).
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Granger CB, Adams PX et al.; APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA297, 43–51 (2007).
   PubMed Web of Science ®Google Scholar
• Atar D, Petzelbauer P, Schwitter J et al.; F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J. Am. Coll. Cardiol.53, 720–729 (2009).
   PubMed Web of Science ®Google Scholar
• Kitakaze M, Asakura M, Kim J et al.; J-WIND Investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet370, 1483–1493 (2007).
   PubMed Web of Science ®Google Scholar
• Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol.45, 1406–1412 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke40, e647–e656 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrario M, Arbustini E, Massa M et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int. J. Cardiol.147(1), 124–131 (2009).
   PubMed Web of Science ®Google Scholar
• Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am. J. Cardiol.104, 1035–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Voors AA, Belonje AM, Zijlstra F et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J.31, 2593–2600 (2010).
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Discovering erythropoietin’s extrahematopoietic functions: biology and clinical promise. Kidney Int.70, 246–250 (2006).
   PubMed Web of Science ®Google Scholar
• Amado LC, Kraitchman DL, Gerber BL et al. Reduction of ‘no-reflow’ phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J. Am. Coll. Cardiol.43, 1291–1298 (2004).
   PubMed Web of Science ®Google Scholar
• Maekawa K, Kawamoto K, Fuke S et al. Effects of intraaortic balloon pumping on the angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with anterior myocardial infarction. Circ. J.70, 37–43 (2006).
   PubMed Web of Science ®Google Scholar
• Sjauw KD, Engstrom AE, Vis MM et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur. Heart J.30, 459–468 (2009).
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J.29, 2909–2945 (2008).
   PubMed Web of Science ®Google Scholar